Tumourmarker related publications 2002-2007: Caj Haglund

  1. Hemmer S, Wasenius V-M, Haglund C, Zhu Y, Knuutila S, Franssila K, Joensuu H. Alterations in the suppressor gene PPP2R1B in parathyroid hyperplasias and adenomas. Cancer Genet Cytogen 2002;134:13-17. IF 1.640
  2. Ristimäki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, Joensuu H, Isola J. Prognostic significance of elevated cyxlooxygenase-2 expression in breast cancer. Cancer Res 2002;62:632-5. IF 7.616
  3. Louhimo J, Finne P, Alfthan H, Stenman U-H, Haglund C. Combination of hCGb, CA 19-9 and CEA with logistic regression improves accuracy in gastrointestinal malignancies. Anticancer Res 2002;22:1759-1764. IF 1.604
  4. Buskens CJ, van Rees BP, Sivula A, Reitsman JB, Haglund C, Bosma PJ, Offerhaus GJ, van Lanschot JJ, Ristimäki A. Prognostic significance of elevated Cyclooxygenase-2 expression in patients with adenocarcinoma of the esophagus. Gastroenterology 2002;122:1800-1807. IF 12.386
  5. Carpelan-Holmström M, Louhimo J, Stenman U-H, Alfthan H, Haglund C. CEA, CA 19-9, and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers. Anticancer Res 2002;22:2311-2316. IF 1.604
  6. Hotakainen K, Haglund C, Paju A, Nordling S, Alfthan H, Rintala E, Stenman U-H. Chorionic gonadotropin b-subunit and core fragment in bladder cancer; mRNA and protein expression in urine, serum or tissue.Eur Urol 2002;41:677-685. IF 3.542
  7. Wiksten J-P, Lundin J, Nordling S, Kokkola A, von Boguslawski K, Haglund C. The prognostic value of p27 in gastric cancer. Oncology 2002;63:180-184. IF 1.985
  8. Louhimo J, Carpelan-Holmström M, Alfthan H, Stenman U-H, Järvinen H.J, Haglund C. Serum hCGb, CA 72-4 and CEA are independent prognostic factors in colorectal cancer. Int J Cancer 2002;101:545-548. IF 4.700
  9. Hotakainen K, Ljungberg B, Haglund C, Nordling S, Stenman U-H. Expression of the free b-subunit of human chorionic gonadotropin in renal cell carcinoma. A prognostic study on tissue and serum. Int J Cancer 2003;104:631-635. IF 4.700
  10. Wiksten J-P, Lundin J, Nordling S, Lundin M, Kokkola A, von Boguslawski K, Haglund C. Tenascin-C expression correlates with prognosis in gastric cancer. Oncology 2003;64:245-250. IF 1.985
  11. Salmenkivi K, Heikkilä P, Liu J, Haglund C, Arola J. VEGF in 105 pheochromocytomas: enhanced expression correlates with malignant outcome. APMIS 2003;111:458-464. IF 2.127
  12. Salmenkivi K, Heikkilä P, Liu J, Haglund C, Louhimo J, Arola J. Lack of histologically suspicious features, proliferative activity, and p53 expression suggests benign diagnosis in pheochromocytomas. Histopathology 2003;43:62-71. IF 2.608
  13. Atula T, Hedström J, Finne P, Leivo I, Markkanen-Leppänen M, Haglund C. Tenascin-C expression and its prognostic significance in oral and pharyngeal squamous cell carcinoma. Anticancer Res 2003;23:3051-3056. IF 1.604
  14. Buskens CJ, Sivula A, Rees van BP, Haglund C, Offerhaus GJA, Lanschot van JJB, Ristimäki A. Comparison of cyclooxygenase 2 expression in adenocarcinomas of the gastric cardia and distal oesophagus. Gut 2003;52:1678-1683. IF 7.692
  15. Erkinheimo T-L, Lassus H, Sivula A, Sengupta S, Furneauf H, Hla T, Haglund C, Butzow R, Ristimäki A. Cytoplasmic HuR expression corelates with poor outcome and with Cyclooxygenase 2 expression in serous ovarian carcinoma. Cancer Res 2003;63:7591-7594. IF 7.616
  16. Juuti A, Nordling S, Louhimo J, Lundin J, Boguslawski von K, Haglund C. Loss of p27 expression is associated with poor prognosis in stage I-II pancreatic cancer. Oncology 2003;65:371-377. IF 1.985
  17. Erkinheimo T-L, Lassus H, Finne P, van Rees BP, Leminen A, Ylikorkala O, Haglund C, Butzow R, Ristimäki A. Elevated cyclooxygenase-2 is associated with altered expression of p53 and SMAD4, amplification of HER-2/neu, and poor outcome in serous ovarian carcinoma. Clin Cancer Res 2004;10:538-545. IF 5.715
  18. Koljonen V, Tukiainen E, Haglund C, Böhling T. Expression of cyclin A in Merkel cell carcinoma. APMIS 2004;112:39-44. IF 2.127
  19. Louhimo J, Alfthan H, Stenman U-H, Haglund C. Serum hCGbeta and CA 72-4 are stronger prognostic factors than CEA, CA 19-9 and CA 242 in pancreatic cancer. Oncology 2004;66:126-131. IF 1.985
  20. Siironen P, Ristimäki A, Nordling S, Louhimo J, Haapiainen R, Haglund C. Expression of COX-2 is increased with age in papillary thyroid cancer. Histopathology 2004;44:490-497. IF 2.608
  21. Carpelan-Holmström M, Louhimo J, Stenman U-H, Alfthan H, Järvinen H, Haglund C. Estimating the probability of cancer with several tumor markers in patients with colorectal disease. Oncology 2004;66:296-302. IF 1.985
  22. Louhimo J, Kokkola A, Alfthan H, Stenman U-H, Haglund C. Preoperative hCGb and CA 72-4 are prognostic factors in gastric cancer. Int J Cancer 2004;111:929-933. IF 4.700
  23. Räty S, Sand J, Alfthan H, Haglund C, Nordback I. Cyst fluid tumour-associated trypsin inhibitor may be helpful in the differentiation of cystic pancreatic lesions. J Gastrointest Surg 2004;8:569-74. IF 2.290
  24. Paju A, Vartiainen J, Haglund C, Itkonen O, von Boguslawski K, Leminen A, Wahlström T, Stenman U-H. Expression of Trypsinogen-1, Trypsinogen-2 and tumor-associated trypsin inhibitor in ovarian cancer: prognostic study on tissue and serum. Clin Cancer Res 2004;10:4761-4768. IF 5.715
  25. Leivonen M, Lundin J, Nordling S, von Boguslawski K, Haglund C. Prognostic value of syndecan-1 expression in breast cancer. Oncology 2004;67:11-18. IF 1.985
  26. Juuti A, Nordling S, Louhimo J, Lundin J, Haglund C. Tenascin-C expression is upregulated in pancreatic cancer and correlates to differentiation. J Clin Pathol 2004;57:1151-1155. IF 2.170
  27. Salmenkivi K, Heikkilä P, Haglund C, Arola J. Malignancy in pheochromocytomas. APMIS 2004;112:551-559. IF 2.127
  28. Koljonen V, Lassus P, Tukiainen E, Ristimäki A, Haglund C, Böhling T. Cyclooxygenase-2 expression in primary Merkel cell carcinoma. J Cutan Pathol 2005;32:55-58. IF 1.333
  29. Carpelan-Holmström M, Nordling S, Pukkala E, Sankila R, Lüttges J, Klöppel G, Haglund C. Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish cancer registry. Gut 2005;54:385-387. IF 7.692
  30. Koljonen V, Jahkola T, Tukiainen E, Granroth G, Haglund C, Böhling T. Tenascin-C in primary Merkel cell carcinoma. J Clin Pathol 2005;58:297-300. IF 2.170
  31. Kokkola A, Louhimo J, Puolakkainen P, Alfthan H, Haglund C, Rautelin H. Helicobacter pylori infection and low serum pepsinogen I level as risk factors for gastric carcinoma. World J Gastroenterol 2005;11:1032-1036. IF 3.318
  32. Siironen P, Nordling S, Louhimo J, Haapiainen R, Haglund C. Immunohistochemical expression of Bcl-2, Ki-67, and p21 in patients with papillary thyroid cancer. Increased Ki-67 expression in older patients. Tumor Biology 2005;26:50-56. IF 1.235
  33. Sivula A, Talvensaari-Mattila A, Lundin J, Joensuu H, Haglund C, Ristimäki A, Turpeenniemi-Hujanen T. Association of Cyclooxygenase-2 and Matrix Metalloproteinase-2 expression in human breast cancer. Breast Cancer Res Tr 2005;89:215-220. IF 4.643
  34. Heinonen M, Bono P, Narko K, Chang S-H, Lundin J, Joensuu H, Furneaux H, Hla T, Haglund C, Ristimäki A. Cytoplasmic HuR expression is a prognostic factor in invasive ductal breast carcinoma. Cancer Res 2005;65:2157-2161. IF 7.616
  35. Wiksten J-P, Lundin J, Nordling S, Lundin M, Kokkola A, Stenman U-H, Haglund C. High tissue expression of tumor-associated trypsin inhibitor (TATI) associates with a more favorable prognosis in gastric cancer. Histopathology 2005;46:380-388. IF 2.608
  36. Koljonen V, Haglund C, Tukiainen E, Böhling T. Neuroendocrine differentiation in primary Merkel cell carcinoma – possible prognostic significance. Anticancer Res 2005;25:853-858. IF 1.604
  37. Siironen P, Louhimo J, Nordling S, Ristimäki A; Mäenpää H, Haapiainen R, Haglund C. Prognostic factors in papillary thyroid cancer. An evaluation of 601 consecutive patients.  Tumor Biology 2005;26:57-64. IF 1.235
  38. Juuti A, Nordling S, Lundin J, Louhimo J, Haglund C. Syndecan-1 expression - a novel prognostic marker in pancreatic cancer. Oncology 2005;68:97-106. IF 1.985
  39. Lundin M, Nordling S, Lundin J, Isola J, Wiksten J-P, Haglund C. Epithelial syndecan-1 expression is associated with stage and grade in colorectal cancer. Oncology 2005;12:306-313. IF 1.985
  40. Lassus P, Ristimäki A, Huuhtanen R, Tukiainen E, Asko-Seljävaara S, Andersson L.C, Miettinen M, Blomqvist C, Haglund C, Böhling T. Cyclooxygenase-2 expression in human soft-tissue sarcomas is related to epithelial differentation. Anticancer Res 2005;25:2669-74. IF 1.604
  41. Sivula A, Buskens C.J, van Rees B.P, Haglund C, Offerhaus G.J, van Lanschot J.J, Ristimäki A. Prognostic role of Cyclooxygenase-2 in neoadjuvant-treated patients with squamous cell carcinoma of the esophagus. Int J Cancer 2005;116:903-908. IF 4.700
  42. Erkinheimo T-L, Sivula A, Lassus H, Heinonen M, Furneaux H, Haglund C, Butzow R, Ristimäki A. Cytoplasmic HuR expression correlates with epithelial cancer cell but not with stromal cell cyclooxygenase-2 expression in mucinous ovarian carcinoma. Gynecol Oncol 2005;99:14-19. IF 2.251
  43. Mrena J, Wiksten J-P, Thiel A, Kokkola A, Pohjola L, Lundin J, Nordling S, Ristimäki A, Haglund C. Cyclooxygenase-2 is an independent prognostic factor in gastric cancer and its expression is regulated by an messenger RNA stability factor HuR. Clin Cancer Res 2005;11:7362-8. IF 5.715
  44. Hotakainen K, Bjartell A, Sankila A, Järvinen R, Paju A, Rintala E, Haglund C, Stenman U-H. Differential expression of trypsinogen and tumor-associated trypsin inhibitor (TATI) in bladder cancer. Int J Oncol 2006;28:95-101. IF 2.681
  45. Thiel A, Heinonen M, Rintahaka J, Hallikainen T, Hemmes A, Dixon D.A, Haglund C, Ristimäki A. Expression of cyclooxygenase-2 is regulated by glycogen synthase kinase-3b in gastric cancer cells. J Biol Chem 2006;281:4564-4569. IF 5.854
  46. Koljonen V, Böhling T, Tukiainen E, Haglund C, Jahkola T. Tenascin-C expression in Merkel cell carcinoma lymph node metastasis. APMIS 2006;114:39-42. IF 2.127
  47. Juuti A, Louhimo J, Nordling S, Ristimäki A, Haglund C. Cyclooxygenase-2 expression correlates with poor prognosis in pancreatic cancer. J Clin Pathol 2006;59:382-386. IF 2.170
  48. Siironen P, Ristimäki A, Narko K, Nordling S, Louhimo J, Andersson S, Haapiainen R, Haglund C. VEGF-C and Cox-2 expression in papillary thyroid cancer. Endocr-relat cancer 2006;13:465-473. IF 4.905
  49. Mrena J, Wiksten J-P, Nordling S, Kokkola A, Ristimäki A, Haglund C. MMP-2 but not MMP-9 associated with Cox-2 and survival in gastric cancer. J Clin Pathol 2006;59:618-623. IF 2.170
  50. Lemeta S, Salmenkivi K, Pylkkänen L, Sainio M, Saarikoski S.T, Arola J, Heikkilä P, Haglund C, Husgafvel-Pursiainen K, Böhling T. Frequent loss of heterozygosity at 6q in pheochromocytoma. Hum Pathol 2006;37:749-54. IF 2.550
  51. Koljonen V, Tukiainen E, Haglund C, Böhling T. Cell cycle control by p21, p27 and p53 in Merkel cell carcinoma. Anticancer Res 2006;26:2209-2212. IF 1.604
  52. Atula T, Hedström J, Ristimäki A, Finne P, Leivo I, Markkanen-Leppänen M, Haglund C. Cyclooxygenase-2 expression in squamous cell carcinoma of the oral cavity and pharynx: association to p53 and clinical outcome. Oncol Rep 2006;16:485-90. IF 1.572
  53. Linder N, Haglund C, Lundin M, Nordling S, Ristimäki A, Kokkola A, Mrena J, Wiksten J-P, Lundin J. Decreased xanthine oxidoreductase is a predictor of poor prognosis in early-stage gastric cancer. J Clin Pathol 2006;59:965-71. IF 2.170
  54. Mrena J, Wiksten J-P, Kokkola A, Nordling S, Haglund C*, Ristimäki A*. Prognostic significance of cyclin A in gastric cancer. * equal contribution. Int J Cancer 2006;119:1897-1901. IF 4.700
  55. Stenman J, Paju A, Rissanen O, Tenkanen T, Haglund C, Räsänen J, Salo J, Stenman U-H, Orpana A. Targeted gene-expression analysis by Genome-controlled reverse transcriptase-PCR. Clin Chem 2006;52:1988-96. IF 7.717
  56. Koljonen V, Tukiainen E, Haglund C, Böhling T. Proliferative activity detected by Ki-67 correlates with poor outcome in Merkel cell carcinoma. Histopathology 2006;49:551-553. IF 2.608
  57. Stenman J, Räsänen J, Tenkanen T, Haglund C, Salo J, Orpana A, and Paju A. Genome-controlled reverse transcriptase-polymerase chain reaction for targeted gene-expression analysis. Scand J Clin Lab Invest 2006;66:597-606. IF 0.946
  58. Railo M, Lundin J, Haglund C, von Smitten K, Nordling S. Ki67, p53, ER-receptors, ploidy and S-phase as long-term prognostic factors in T1 node negative breast cancer. Tumor Biology 2007;28:45-51. IF 1.235
  59. Juuti A, Lundin J, Nordling S, Haglund C. Epithelial MMP-2 expression correlates with worse prognosis in pancreatic cancer. Oncology 2007;71:61-68. IF 1.985